Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetesTHE WOODLANDS, Texas, June ...

Lexicon Pharmaceuticals announced that it will present data from a study on sotagliflozin's effects on hypoglycemia in individuals with type 1 diabetes at the upcoming American Diabetes ...

Industry watchers responded mostly positively to the commissioner’s new voucher program, but worries remain over staffing cuts at the agency.

Lexicon Pharmaceuticals, Inc. (LXRX) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Get the detailed quarterly/annual income statement for Lexicon Pharmaceuticals, Inc. (LXRX). Find out the revenue, expenses and profit or loss over the last fiscal year.

It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...